MedTrace Logo

Tranexamic Acid During Excisional Burn Surgery

NCT05507983 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2024-03-13

No results posted yet for this study

Summary

The purpose of this study is to access the efficacy of the drug tranexamic acid in reducing blood loss during burn excision surgery.

Conditions

  • Burns
  • Blood Loss, Surgical
  • Blood Loss
  • Tranexamic Acid
  • Burn Excisional Surgery

Interventions

DRUG

Tranexamic acid

Tranexamic acid 1500 mg

DRUG

Placebo

Placebo, sodium chloride 0.9%

Sponsors & Collaborators

  • Association of Dutch Burn Centres

    collaborator OTHER

  • Martini Hospital Groningen

    collaborator OTHER

  • Red Cross Hospital Beverwijk

    collaborator OTHER

  • Maasstad Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2025-01-01
Completion
2025-04-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05507983 on ClinicalTrials.gov